Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thelinh Nguyen

Vascular Surgery Reno, NV Medical Doctor

NPI 1720031982 CMS profile 259897

540 W Plumb Ln Ste 200, Reno, NV 89509

Open in the dashboard

General payments

$16,223

205 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thelinh Nguyen of Reno, NV is reported in the CMS Open Payments database as having received $16,223 across 205 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 78th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,982 20
2024 General $2,702 27
2023 General $2,425 31
2022 General $1,736 29
2021 General $2,308 30
2020 General $1,676 30
2019 General $2,393 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thelinh Nguyen
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Thelinh Nguyen were reported at $2,982. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Thelinh Nguyen Vascular Surgery median Middle half National median
2019 $2,393 $796 $226–$2,363 $163
2020 $1,676 $348 $118–$1,110 $114
2021 $2,308 $471 $158–$1,421 $132
2022 $1,736 $725 $222–$2,183 $149
2023 $2,425 $836 $257–$2,440 $160
2024 $2,702 $909 $252–$2,619 $164
2025 $2,982 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $6,130 80 payments
  2. Shockwave Medical, Inc $3,241 24 payments
  3. Medtronic Vascular, Inc. $1,893 32 payments
  4. W. L. Gore & Associates, Inc. $1,801 16 payments
  5. LeMaitre Vascular, Inc. $693 12 payments
  6. Cook Medical LLC $468 9 payments
  7. Boston Scientific Corporation $411 4 payments
  8. Inari Medical, Inc. $360 2 payments
  9. Penumbra, Inc. $203 2 payments
  10. Olympus America Inc. $176 2 payments
  11. Other $848 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $15,462 203 payments
  2. Travel and Lodging $716 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $45 1 payment
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $2,793 44 payments
  2. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Cardiology $1,695 10 payments
  3. Valiant Captivia $1,491 11 payments
  4. Endurant Aortic Stent Grafts $1,389 25 payments
  5. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Lithoplasty $1,278 11 payments
  6. Endurant Aortic Stent Grafts $806 11 payments
  7. EXCLUDER Conformable AAA Endoprosthesis with Active Control $739 6 payments
  8. IN.PACT Admiral $527 6 payments
  9. Conformable TAG Thoracic Endoprosthesis $516 5 payments
  10. CT THROMBECTOMY SYSTEM KIT $360 2 payments
  11. Other $5,123 84 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

92

Median for Vascular Surgery: 122

Drug cost

$991

Median for Vascular Surgery: $14,135

Branded share of claims

59.8%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 41 $518
Cilostazol Generic 24 $362
Simvastatin Generic 13 $77
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 14 $33

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$109,162

Medicare's payments for the services billed

Medicare patients

231

Average age 74

Services billed

536

102 women, 129 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 61%
Diabetes 48%
Ischemic heart disease 45%
Heart failure 41%
Arthritis 40%
Atrial fibrillation 33%
COPD 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record